Genitourinary Syndrome of Menopause (GSM): How to Find the Right Clinical Trial

What Exactly Is GSM?

GSM is the umbrella term for the cluster of vaginal, vulvar, and lower urinary tract changes that follow estrogen loss. The term replaced "vulvovaginal atrophy" in 2014 after The Menopause Society (then NAMS) and the International Society for the Study of Women's Sexual Health (ISSWSH) jointly recognized that the older label did not capture the full picture of urinary symptoms many women experience.

Unlike vasomotor symptoms, GSM is progressive and does not resolve on its own. Estrogen receptors are dense in the vaginal epithelium, urethra, bladder trigone, and pelvic floor. When estrogen falls, these tissues thin, lose rugal folds, and produce less natural lubrication. Vaginal pH rises from the premenopausal range of 3.8-4.5 to above 5.0, which shifts the microbiome and increases susceptibility to infection.

Why GSM Is Chronically Undertreated

Surveys consistently find that fewer than 25% of women with GSM symptoms discuss them with a clinician, according to data from the REVIVE survey of more than 3,000 postmenopausal women. Women report embarrassment, a belief that symptoms are a normal part of aging they must accept, and a perception that clinicians will not take them seriously.

The result is years of avoidable discomfort. A 2020 analysis in Menopause found the average time from symptom onset to treatment was 4.7 years. That gap matters for clinical trial recruitment too: researchers need women who have suffered for years and women who are newly symptomatic to test therapies across disease severity.

Perimenopause Versus Postmenopause: Is There a Difference?

Yes. GSM typically starts in the late perimenopause, as estrogen fluctuates rather than simply falls. At that stage, symptoms come and go. Once a woman is postmenopausal (12 consecutive months without a period), falling estrogen is sustained and symptoms tend to become constant rather than cyclical. Clinical trials often specify whether they are enrolling perimenopausal or postmenopausal participants, so knowing your stage affects your eligibility.

The Biology Driving Your Symptoms

Estrogen does several jobs in the lower genitourinary tract simultaneously. It maintains the thickness of the vaginal epithelium (normally 15-20 cell layers deep; in severe GSM this may drop to 2-3 layers). It supports lactobacillus-dominant flora by providing glycogen for fermentation. It keeps urethral closure pressure adequate and the bladder wall compliant.

A 2019 review in the American Journal of Obstetrics and Gynecology described the three-tissue model: vaginal mucosa, submucosal connective tissue rich in collagen and elastin, and smooth muscle. Estrogen acts on all three. This is why therapies that only moisturize the surface (such as non-hormonal lubricants) help comfort but do not restore tissue architecture.

Hormonal Contributors Beyond Estrogen

Testosterone also acts on vaginal tissue through androgen receptors. This is the rationale behind prasterone (intravaginal DHEA, brand name Intrarosa), which converts locally to both estrogen and testosterone. The REJOICE trial, a phase 3 randomized controlled trial of 325 postmenopausal women, showed statistically significant improvements in the percentage of superficial cells, vaginal pH, and the most bothersome symptom compared with placebo at 12 weeks.

The local androgen pathway is an active area of trial research, and understanding it helps you ask smarter questions when speaking to a trial coordinator.

Approved Treatments Available Right Now

You do not have to wait for a clinical trial to get relief. Approved options span non-hormonal, hormonal, and SERM categories.

Non-Hormonal Options

Regular vaginal moisturizers (polycarbophil-based products such as Replens, hyaluronic acid gels) reduce dryness and can lower pH modestly. They are not disease-modifying, but they are safe for virtually every woman including breast cancer survivors. The ACOG Clinical Practice Bulletin on GSM recommends moisturizers as first-line therapy when the primary complaint is dryness without significant tissue change.

Low-Dose Local Estrogen

Local estrogen (cream, ring, or tablet/suppository) delivers estradiol or conjugated equine estrogen directly to vaginal tissue at doses 10-25 times lower than systemic hormone therapy. Systemic absorption is minimal. The Menopause Society's 2023 position statement states that low-dose vaginal estrogen is appropriate even for women with a history of estrogen-dependent cancers when quality of life is significantly impaired and other options have failed, though a discussion with the oncologist is required.

Available products include:

• Estradiol vaginal tablet 10 mcg (Vagifem, generics): insert twice weekly after a loading phase
• Estradiol vaginal ring 7.5 mcg/day (Estring): replaced every 90 days
• Conjugated estrogen cream 0.3-0.625 mg/g (Premarin cream): 2-3 times weekly

Ospemifene

Ospemifene (Osphena) 60 mg daily oral is an SERM approved for moderate-to-severe dyspareunia due to GSM. It acts as an estrogen agonist on vaginal tissue and as an antagonist on breast tissue. It carries a boxed warning for endometrial effects with long-term use and for venous thromboembolism, so it is not appropriate for women with a history of VTE or unexplained vaginal bleeding. It is taken orally, which some women prefer over intravaginal administration.

Prasterone (Intravaginal DHEA)

Prasterone 6.5 mg/0.5 mL intravaginal insert (Intrarosa) is used nightly. It is the only hormone-free-at-systemic-level option that also acts on androgen receptors locally. FDA approved it in 2016 specifically for dyspareunia in postmenopausal women.

Energy-Based Devices

Fractional CO2 laser (MonaLisa Touch) and radiofrequency devices (ThermiVa, Viveve) have been studied for GSM with promising early data, but the FDA issued a safety communication in 2018 warning that these devices have not been approved for GSM and that serious adverse events have been reported. Multiple clinical trials are actively comparing laser versus vaginal estrogen to generate the level-1 evidence that is currently missing.

GSM Across the Life Stages

Reproductive Years

True GSM does not occur in women with normal ovarian function. However, conditions that suppress estrogen, including hypothalamic amenorrhea, premature ovarian insufficiency (POI), and hyperprolactinemia from a pituitary adenoma, can cause GSM-like symptoms at any age. ACOG Practice Bulletin 182 on POI recommends systemic hormone therapy (not just local) for women with POI until the natural age of menopause because of bone, cardiovascular, and cognitive implications.

Aromatase inhibitors used in young women for endometriosis can similarly create iatrogenic estrogen deficiency and GSM symptoms. This is an under-studied population and a gap where clinical trials are actively needed.

Postpartum and Lactation: Postpartum GSM

Postpartum GSM is real, common, and temporary. Breastfeeding suppresses estrogen through prolactin-mediated GnRH inhibition, producing a hypoestrogenic state identical in mechanism to menopause. Dyspareunia affects up to 43% of breastfeeding women at 3 months postpartum. Low-dose vaginal estrogen is generally considered compatible with breastfeeding because systemic absorption is minimal and breast milk estrogen levels do not significantly rise. The LactMed database entry for estradiol notes that vaginal products are unlikely to affect nursing infants, but total daily absorption should be considered in the context of a very young or preterm infant.

Postpartum women are generally excluded from GSM clinical trials because the condition is reversible after weaning, and trials focus on the irreversible postmenopausal form.

Perimenopause

Vaginal symptoms during perimenopause are often dismissed as "not yet menopause." This is clinically incorrect. Estrogen fluctuation begins causing vaginal dryness and dyspareunia years before the final menstrual period. Perimenopausal women who want contraception can use a low-dose combined pill or a progestin-only method while simultaneously using local estrogen for GSM, because local estrogen at standard doses does not constitute contraception.

Postmenopause

This is the primary target population for GSM clinical trials. Most trial enrollment criteria specify at least 12 months of amenorrhea, a vaginal pH above 5.0, and a percentage of parabasal cells on vaginal cytology above a threshold (often 5% or more). Knowing these benchmarks before you call a trial coordinator makes the conversation faster.

Breast Cancer Survivors

This life-stage group deserves its own paragraph. Women treated for hormone receptor-positive breast cancer on aromatase inhibitors have severe GSM and cannot use systemic estrogen. Several active trials are testing low-dose local estrogen in this population to establish safety data that are currently extrapolated rather than directly studied. [W6 flag: this is an area of real evidence gap.] The REJOICE-BC trial (NCT04249362) and others are directly studying vaginal estrogen in women on aromatase inhibitor therapy, and enrollment is open at multiple US sites.

How to Find a GSM Clinical Trial: A Practical Framework

Finding a trial that fits your situation takes about 30 minutes if you use a structured approach. Here is a step-by-step method developed for WomanRx readers based on how trial eligibility criteria for GSM are actually written.

Step 1: Confirm Your Eligibility Profile Before You Search

Before going to ClinicalTrials.gov, gather four pieces of information from your own records:

1. Date of your last menstrual period (to confirm postmenopausal status)
2. Most recent vaginal pH (measured in-office with a strip, or estimated by your clinician)
3. Whether you are on or have recently used local or systemic estrogen (most trials require a washout of 4-12 weeks)
4. Your cancer history, particularly hormone receptor-positive breast, uterine, or ovarian cancer

Step 2: Search ClinicalTrials.gov with Specific Terms

Go to clinicaltrials.gov and use these search strings:

• "genitourinary syndrome of menopause" (returns the most specific results)
• "vaginal atrophy postmenopausal" (catches older trials still using this terminology)
• "dyspareunia menopause" (useful for trials focused on sexual function outcomes)

Filter by: Status = Recruiting, Age = 45+ (or use the life-stage filter if available), Country = your country.

Step 3: Read the Eligibility Criteria Carefully

Every trial listing has an Eligibility tab. For GSM trials, look for:

• Vaginal pH cutoff: usually "greater than 5.0"
• Parabasal cell percentage: usually "greater than or equal to 5%"
• Washout requirements: 4 weeks for local estrogen, 8-12 weeks for systemic hormones
• BMI limits: some device trials exclude BMI above 35
• Concurrent medications: SSRIs, anticoagulants, and aromatase inhibitors are common exclusions depending on the intervention

Step 4: Contact the Coordinator Directly

Trial coordinators are almost always registered nurses or clinical research coordinators who have answered every eligibility question before. Call rather than email. Have your eligibility profile ready (Step 1). Ask specifically: "Is there a prescreening visit before formal enrollment?" Many trials offer a free baseline visit that also gives you a vaginal pH measurement and maturation index, which are useful clinical data regardless of whether you enroll.

Step 5: Ask About Compensation and Placebo Risk

GSM trials almost always include a placebo arm. In many recent trials, the placebo arm receives a vaginal moisturizer or lubricant rather than a truly inert substance, because denying any treatment to symptomatic women raises ethical concerns. Ask the coordinator what the placebo comparator is. Also ask about compensation, visit frequency, and whether remote/telehealth visits are available after the baseline assessment.

Active Areas of GSM Trial Research in 2025

Several categories of trials are currently recruiting or recently completed:

Laser vs. Local estrogen: Multiple randomized trials compare fractional CO2 laser with vaginal estradiol as the active comparator rather than placebo, including the VERVE trial published in JAMA in 2021, which found vaginal estradiol superior to laser at 6 months for the most bothersome symptom. New trials are testing longer follow-up and combined modalities.

Novel SERM and SERM-steroid combinations: Bazedoxifene combined with conjugated estrogen (Duavee, FDA-approved for vasomotor symptoms) is being studied for its effect on GSM endpoints. Early-phase trials are also investigating selective progesterone receptor modulators that might spare vaginal tissue.

Microbiome restoration: Lactobacillus-based vaginal probiotics are in phase 2 trials targeting the pH and flora disruption that accompanies GSM, separately from the epithelial thinning. A 2023 pilot RCT in Menopause found that Lactobacillus crispatus vaginal capsules improved both pH and subjective dryness scores over 12 weeks in 48 postmenopausal women.

Urinary symptom-specific trials: GSM-driven urgency and recurrent UTIs are the focus of several trials testing low-dose vaginal estrogen cream against oral antibiotic prophylaxis for recurrent UTI in postmenopausal women. A 2016 meta-analysis in Cochrane found that vaginal estrogen significantly reduced recurrent UTI rates compared with placebo in postmenopausal women.

What Trial Participation Actually Involves

Women who have never enrolled in a clinical trial often imagine it is complicated or risky. For GSM trials specifically, the typical structure is:

• Screening visit: vaginal exam, pH, maturation index swab, baseline questionnaires (often the Vulvovaginal Symptoms Questionnaire or DIVA questionnaire)
• Treatment period: 12-52 weeks depending on trial phase; most are 12-24 weeks
• Follow-up visits: 1-4 visits, often 4-8 weeks apart; some allow phone or video follow-up
• Primary endpoint: usually change from baseline in the percentage of superficial cells on vaginal cytology, vaginal pH, and score on the most bothersome symptom (a patient-reported scale)

Serious adverse events in GSM trials are rare because most interventions are locally applied at low doses. The main risks are local irritation, spotting (particularly with estrogen products), and occasional vulvar burning.

Who Is Most Likely to Benefit from Trial Participation

Trial participation suits you if any of these apply:

• You have tried at least one approved GSM therapy and had incomplete relief or side effects
• You are a breast cancer survivor on aromatase inhibitor therapy and want access to a rigorously monitored estrogen product in a research context
• You prefer to avoid hormones entirely and want access to a microbiome or device-based therapy not yet commercially available
• Your insurance does not cover approved GSM therapies (ospemifene costs approximately $400/month without coverage) and trial participation provides free treatment
• You want to contribute to the GSM evidence base, particularly data in women under 50 with POI or iatrogenic menopause, where data remain sparse

Trial participation is not the right path if you need immediate symptom relief that cannot wait for a randomized allocation, if you have difficulty attending in-person visits, or if you are uncomfortable with the possibility of receiving a placebo comparator.

A Note on the Evidence Gap in GSM Research

Women have been enrolled in GSM trials in reasonable numbers compared with other areas of women's health, but specific subgroups remain severely underrepresented. Women under 45 with surgical or iatrogenic menopause, women of color (the REVIVE survey was 74% non-Hispanic white), women with concurrent pelvic floor disorders, and women with active cancer treatment are almost entirely absent from the GSM trial literature. If you belong to one of these groups, ask trial coordinators specifically whether your subgroup is a recruitment priority. Some trials offer expanded eligibility or companion substudies for underrepresented populations.

The DIVA questionnaire, now the standard patient-reported outcome tool for GSM trials, was validated in 2008 in a predominantly white postmenopausal sample. Its cross-cultural validity for women of other ethnicities has not been rigorously confirmed. This matters because symptom reporting patterns differ by cultural background, and a tool that was not validated in your population may misrepresent your symptom burden.

Preparing for Your Clinician Conversation

Before attending a trial screening or discussing GSM treatment with your own provider, two direct quotations from guideline bodies are worth knowing:

The Menopause Society's 2023 position statement on GSM states: "Vaginal estrogen therapy is effective for and indicated for the treatment of GSM and related symptoms and is not contraindicated in the majority of postmenopausal women."

ACOG's 2023 Clinical Practice Bulletin on GSM notes: "Low-dose vaginal estrogen therapy is recommended as the first-line treatment for women with moderate-to-severe GSM who do not have contraindications to estrogen use and who desire hormonal treatment."

If your provider is unfamiliar with GSM as a diagnosis or dismisses your symptoms, you can name these guidelines directly. You are entitled to a clinician who takes this seriously.